Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413195 | 0.90 | PDE10A (0.41) | PDE10ANR3C1IRAK4PGRLRRK2 | |
| SCHEMBL413181 | 0.89 | NR3C1 (0.49) | PDE10ANR3C1IRAK4PGR | |
| SCHEMBL837324 | 0.87 | NR3C1 (0.49) | PDE10ANR3C1IRAK4PGR | |
| SCHEMBL851374 | 0.87 | NR3C1 (0.49) | PDE10ANR3C1IRAK4PGR | |
| SCHEMBL413192 | 0.84 | NR3C1 (0.45) | NR3C1PGR | |
| SCHEMBL442110 | 0.82 | NR3C1 (0.60) | PDE10ANR3C1PGR | |
| SCHEMBL28785127 | 0.80 | PDE10A (0.54) | PDE10ANR3C1IRAK4 | |
| SCHEMBL411954 | 0.79 | NR3C1 (0.50) | PDE10ANR3C1PGR | |
| SCHEMBL837279 | 0.79 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL851379 | 0.79 | NR3C1 (0.52) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | PDE10A 315/4885NR3C1 1/4885IRAK4 1721/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | PDE10A 304/4885NR3C1 1/4885IRAK4 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.